Allergic Reactions with MCC DRG: Medicare Payment Guide

Summary & Overview

Allergic Reactions with MCC: Inpatient Reimbursement Overview

DRG 915 pertains to inpatient stays for allergic reactions complicated by a Major Complication or Comorbidity, reflecting cases with increased clinical severity and resource needs. Understanding this Diagnosis-Related Group is important for inpatient reimbursement because assignment affects the relative payment weight and overall Medicare payment for the episode.

Allergic Reactions with Major Complication or ComorbidityDRG Allergic Reactions with MCCDRG 915Diagnosis-Related GroupInpatient ReimbursementMedicareAllergy and ImmunologyCritical CareEmergency Medicine

DRG 915 Overview

DRG 915 covers inpatient encounters for allergic reactions where a Major Complication or Comorbidity is present, typically including severe systemic responses requiring intensive monitoring or organ support. This Diagnosis-Related Group captures higher resource use driven by severity, extended length of stay, and intervention intensity. It is important for Medicare payment because the presence of a Major Complication or Comorbidity increases the relative payment weight compared with lower-severity groupings. Correct clinical documentation and coding determine assignment to this Diagnosis-Related Group and thus influence reimbursement.

National Payment Rates

Across commercial payers the observed rate range spans from about $370 (BCBS minimum) up to $59K (Anthem maximum), with mean payer averages clustering between roughly $15K and $28K. The widest spread is between BCBS’s minimum reported value and Anthem’s maximum (~$59K), reflecting considerable variability across payers. See the table and chart below for payer-level percentiles and distributions.

Mean Rates by Payer — National — DRG 915

The CMS 2023 data reflect national Medicare fee-for-service inpatient payments as published in the CMS Provider Utilization and Payment Data program. The table below shows average total payment ($17.6k), average submitted covered charges ($76.8k), average Medicare payment amount ($14.2k), and total discharges (1.8k).

State Payment Rates

State: Alaska1 / 49

Alaska Benchmarks

Alaska payer means for DRG 915 span from $25K (Blue Cross Blue Shield and Anthem) up to $42K (Cigna), reflecting a substantial within-state spread. Cigna’s mean at $42K is the most notable deviation relative to typical national benchmarks, sitting well above other local payers. See the table and chart below for payer-level detail.

Key Insights for Alaska

Highest payer: Cigna (mean $42K); Lowest payer: Blue Cross Blue Shield/Anthem (mean $25K).
Alaska’s payer means range ($25K–$42K) skews higher than some national averages, with Cigna notably above the national Cigna mean context, indicating a meaningful upward deviation for that payer.

Clinical Trials

Acute emergency intervention trials evaluating rapid treatments for severe, life-threatening allergic reactions (anaphylaxis, angioedema) in hospitalized patients: these studies focus on protocols for immediate airway management, dosing and timing of emergency medications, and escalation-of-care algorithms in the ED and inpatient setting. The patient population includes adults and children admitted with an acute allergic reaction accompanied by major complication(s) (e.g., respiratory failure, shock) requiring critical care interventions. Results inform hospital protocols, resource utilization, and short-term outcomes that are directly relevant to providers managing high-acuity cases and payers concerned with cost, length of stay, and avoidance of intensive care utilization.
Comparative effectiveness trials of inpatient management strategies for complex allergic reactions with major complications: these trials compare treatment pathways (for example, different corticosteroid regimens, adjunctive immunomodulatory approaches, or observation versus early escalation to intensive monitoring) in patients who have survived the initial emergency phase but remain at high risk for progression or biphasic reactions. The studied population consists of hospitalized patients with severe allergic reactions and comorbidities that complicate management (e.g., chronic respiratory disease, cardiovascular disease, or immunosuppression). Evidence from these studies guides clinicians on best practices to reduce readmissions, minimize complications, and optimize inpatient resource use, which matters to payers tracking post-discharge outcomes and cost-effectiveness.
Post-discharge outcomes and health services research examining long-term sequelae, recurrence risk, and systems-level care pathways after a hospitalization for an allergic reaction with major complication: these observational cohort studies and pragmatic trials assess rates of recurrence, adherence to follow-up allergy/immunology care, effectiveness of discharge planning (education, prescriptions like epinephrine autoinjectors, outpatient referrals), and the impact of care coordination on downstream utilization. The population includes survivors of severe inpatient allergic reactions across age groups, with attention to social determinants of health and access to outpatient specialty care. Findings are critical for designing care transitions that lower readmission and ED revisit rates, inform coverage decisions for preventive interventions, and help payers and health systems allocate post-acute resources effectively.

Other Injury, Poisoning and Toxic Effect Diagnoses without MCC: Inpatient Reimbursement Overview

903-WOUND-DEBRIDEMENTS-FOR-INJURIES-WITHOUT-CC-MCC

Wound Debridements for Injuries without CC/MCC: Inpatient Reimbursement Overview

904-SKIN-GRAFTS-FOR-INJURIES-WITH-CC-MCC

Skin Grafts for Injuries with CC/MCC: Inpatient Reimbursement Overview

918-POISONING-AND-TOXIC-EFFECTS-OF-DRUGS-WITHOUT-MCC

Poisoning and Toxic Effects of Drugs without MCC: Inpatient Reimbursement Overview

902-WOUND-DEBRIDEMENTS-FOR-INJURIES-WITH-CC

Wound Debridements for Injuries with CC: Inpatient Reimbursement Overview

913-TRAUMATIC-INJURY-WITH-MCC

Traumatic Injury with MCC: Inpatient Reimbursement Overview

906-HAND-PROCEDURES-FOR-INJURIES

Hand Procedures for Injuries: Inpatient Reimbursement Overview

917-POISONING-AND-TOXIC-EFFECTS-OF-DRUGS-WITH-MCC

Poisoning and Toxic Effects of Drugs with MCC: Inpatient Reimbursement Overview

909-OTHER-O-R-PROCEDURES-FOR-INJURIES-WITHOUT-CC-MCC

Other O.R. Procedures for Injuries without CC/MCC: Inpatient Reimbursement Overview

908-OTHER-O-R-PROCEDURES-FOR-INJURIES-WITH-CC

Other O.R. Procedures for Injuries with CC: Inpatient Reimbursement Overview

Showing 1–10 of 19

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Average Total Payment	Average Submitted Charges	Average Medicare Payment	Total Discharges
$18K	$77K	$14K	1.8K